120 related articles for article (PubMed ID: 34332951)
1. Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey.
Leong JY; Pinkhasov R; Chandrasekar T; Shapiro O; Daneshvar M; Jacob J; Sanford T; Bratslavsky G; Goldberg H
Eur Urol Focus; 2022 Sep; 8(5):1125-1132. PubMed ID: 34332951
[TBL] [Abstract][Full Text] [Related]
2. Disparities Associated with Shared Decision-making in Prostate Cancer Screening.
Basin MF; Crane K; Basnet A; Chandrasekar T; Shapiro O; Jacob JM; Bratslavsky G; Goldberg H
Eur Urol Focus; 2023 Nov; 9(6):1008-1015. PubMed ID: 37198068
[TBL] [Abstract][Full Text] [Related]
3. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
4. Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.
Leyva B; Persoskie A; Ottenbacher A; Hamilton JG; Allen JD; Kobrin SC; Taplin SH
J Cancer Educ; 2016 Dec; 31(4):693-701. PubMed ID: 26498649
[TBL] [Abstract][Full Text] [Related]
5. Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey.
Johnson JA; Moser RP; Ellison GL; Martin DN
J Community Health; 2021 Apr; 46(2):389-398. PubMed ID: 33064229
[TBL] [Abstract][Full Text] [Related]
6. Does a prior cancer diagnosis impact PSA testing? Results from the National Health Interview Survey.
Lazarovich A; Chandrasekar T; Basnet A; Bratslavsky G; Goldberg H
Can J Urol; 2023 Jun; 30(3):11551-11557. PubMed ID: 37344467
[TBL] [Abstract][Full Text] [Related]
7. Temporal and Racial Trends in Prostate-specific Antigen Screening for U.S. Men With a Family History of Prostate Cancer.
Dalela D; Malchow T; Butaney M; Majdalany S; Corsi NJ; Rakic I; Sood A; Rogers C; Abdollah F
Urol Pract; 2023 Sep; 10(5):484-492. PubMed ID: 37347799
[TBL] [Abstract][Full Text] [Related]
8. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
9. Predictors of prostate-specific antigen testing in men aged ≥55 years: A cross-sectional study based on patient-reported outcomes.
Leong JY; Chandrasekar T; Berlin A; Klaassen Z; Wallis CJ; Ahmad AE; Herrera-Caceres JO; Perlis N; Fleshner NE; Goldberg H
Int J Urol; 2020 Sep; 27(9):711-718. PubMed ID: 32476206
[TBL] [Abstract][Full Text] [Related]
10. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
[TBL] [Abstract][Full Text] [Related]
11. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study.
Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
[TBL] [Abstract][Full Text] [Related]
12. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test.
McCormick ME; Haile ZT
J Cancer Educ; 2023 Aug; 38(4):1313-1321. PubMed ID: 36652189
[TBL] [Abstract][Full Text] [Related]
14. Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
Avery KN; Metcalfe C; Vedhara K; Lane JA; Davis M; Neal DE; Hamdy FC; Donovan JL; Blazeby JM
Eur Urol; 2012 Oct; 62(4):649-55. PubMed ID: 22244151
[TBL] [Abstract][Full Text] [Related]
15. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
16. Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States.
Fedewa SA; Gansler T; Smith R; Sauer AG; Wender R; Brawley OW; Jemal A
Ann Fam Med; 2018 Mar; 16(2):139-144. PubMed ID: 29531105
[TBL] [Abstract][Full Text] [Related]
17. Low-Value Prostate Cancer Screening Among Young Men With Private Insurance.
Lange SM; Vehawn J; Choudry MM; Ambrose JP; Cluff CM; Haaland BA; Paudel N; Chipman J; Hanson HA; O'Neil BB
Urol Pract; 2024 Jan; 11(1):110-115. PubMed ID: 37747942
[TBL] [Abstract][Full Text] [Related]
18. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
19. Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006.
Zhu Y; Sorkin JD; Dwyer D; Groves C; Steinberger EK
Prev Chronic Dis; 2011 Sep; 8(5):A114. PubMed ID: 21843417
[TBL] [Abstract][Full Text] [Related]
20. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
